odmj OncoDaily Medical Journal ODMJ 3067-6444 OncoDaily Medical Journal US 8309 10.69690/ODMJ-001-1026-8309 Original Research Limited Prognostic Value of Baseline Curie Score in Children with High-Risk Neuroblastoma Treated with Contemporary Multi-modal Therapy: A Single-Center Retrospective Cohort Study Malaeb Farah Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia farahamalaeb@gmail.com Bez Intidhar El Department of Nuclear Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

Department of Nuclear Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

 https://orcid.org/0000-0002-3779-0259 Rayis Mohamed Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

 https://orcid.org/0000-0003-0304-4810 Ullah Zaheer Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

 Alhazzaa Sawsan Department of Nuclear Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

Department of Nuclear Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

 https://orcid.org/0009-0006-3961-5397 Abdelnaser Ali Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

Ali Abdelnaser; Department of Pediatric Hematology and Oncology, King Fahad Medical City, Riyadh, Saudi Arabia

 14 10 2026 Received: 16072026 Accepted: 21092026 ODMJ-001-1026-8309 Copyright (c) 2026 OncoDaily Medical Journal 2026 OncoDaily Medical Journal 123I-MIBG Curie Score Dinutuximab Induction Chemotherapy Metastatic Burden Neuroblastoma Radiation Therapy production-ready-file-url Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. Sharma R, Yadav J, Bhat SA, et al. Emerging trends in neuroblastoma diagnosis, therapeutics, and research. Mol Neurobiol. 2025;62(5):6423-6466. Thakur A, Dijkstra A. Hallmarks of neuroblastoma—pathophysiology, diagnosis, and therapeutic interventions. Cancer Nexus. 2025;1(2). Sainero-Alcolado L, Sjöberg Bexelius T, Santopolo G, et al. Defining neuroblastoma: from origin to precision medicine. Neuro Oncol. 2024;26(12):2174-2192. Katta SS, Nagati V, Paturi ASV, et al. Neuroblastoma: emerging trends in pathogenesis, diagnosis, and therapeutic targets. J Control Release. 2023;357:444-459. De Bona A, Barbieri M, Rinaldi N, Esposito S. Neuroblastoma in childhood: biological insights, risk stratification, and advances in multimodal therapy. J Clin Med. 2026;15(3):1101. Wahba A, Wolters R, Foster JH. Neuroblastoma in the era of precision medicine: a clinical review. Cancers (Basel). 2023;15(19):4722. Streby KA, Parisi MT, Shulkin BL, et al. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2023;70(8). Yanik GA, Parisi MT, Naranjo A, et al. Validation of postinduction Curie scores in high-risk neuroblastoma: a Children’s Oncology Group and SIOPEN Group report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59(3):502-508. Decarolis B, Schneider C, Hero B, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013;31(7):944-951. Riaz S, Bashir H, Khan SJ, Qazi A. I-131 mIBG scintigraphy Curie versus SIOPEN scoring: prognostic value in stage 4 neuroblastoma. Mol Imaging Radionucl Ther. 2018;27(3):121-125. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237-1243. Littooij A, Olianti C, Brisse H, et al. Imaging of high-risk neuroblastoma: recommendations from SIOPEN Radiology and Nuclear Medicine Specialty Committees. Pediatr Blood Cancer. 2026;73(5). Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013;54(4):541-548. Mayampurath A, Ramesh S, Michael D, et al. Predicting response to chemotherapy in patients with newly diagnosed high-risk neuroblastoma: a report from the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021;5:1181-1188. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334. Sánchez-Vañó R, Balaguer J, Borrego-Dorado I, et al. Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma. Clin Transl Oncol. 2025;27(6):2401-2415. Mora J, Chan GCF, Morgenstern DA, et al. Reduction in Curie score in neuroblastoma patients treated with naxitamab. J Clin Oncol. 2023;41(16 Suppl):10042.